Nektar Therapeutics (NKTR) 주식 개요
바이오 제약 회사인 Nektar Therapeutics는 미국 및 전 세계에서 면역 치료 분야의 의약품을 발견하고 개발하는 데 주력하는 회사입니다. 자세히 보기
NKTR Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Nektar Therapeutics 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$69.76 |
| 52주 최고가 | US$109.00 |
| 52주 최저가 | US$33.40 |
| 베타 | 1.15 |
| 1개월 변동 | -4.46% |
| 3개월 변동 | 14.09% |
| 1년 변동 | 43.30% |
| 3년 변동 | 558.92% |
| 5년 변동 | -71.83% |
| IPO 이후 변동 | 24.02% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Aug 21
NKTR: Late Stage Dermatology Trials And Cash Runway Will Drive Future Upside
The analyst price target for Nektar Therapeutics has been revised from $153.25 to $144.40 as analysts factor in a more cautious revenue outlook for rezpeg, along with higher assumed discount rates. This is partially offset by updated expectations for margins and future P/E levels informed by recent Street research.분석 기사 • Aug 19
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
Last week, you might have seen that Nektar Therapeutics ( NASDAQ:NKTR ) released its quarterly result to the market...
새로운 내러티브 • Aug 17
Long Drug Development Timelines Will Test Autoimmune Pipeline Yet Could Ultimately Reward Patience
Catalysts About Nektar Therapeutics Nektar Therapeutics develops immune modulating therapies with a focus on autoimmune and inflammatory diseases. What are the underlying business or industry changes driving this perspective?Recent updates
내러티브 업데이트 • Aug 21
NKTR: Late Stage Dermatology Trials And Cash Runway Will Drive Future Upside
The analyst price target for Nektar Therapeutics has been revised from $153.25 to $144.40 as analysts factor in a more cautious revenue outlook for rezpeg, along with higher assumed discount rates. This is partially offset by updated expectations for margins and future P/E levels informed by recent Street research.분석 기사 • Aug 19
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
Last week, you might have seen that Nektar Therapeutics ( NASDAQ:NKTR ) released its quarterly result to the market...새로운 내러티브 • Aug 17
Long Drug Development Timelines Will Test Autoimmune Pipeline Yet Could Ultimately Reward Patience
Catalysts About Nektar Therapeutics Nektar Therapeutics develops immune modulating therapies with a focus on autoimmune and inflammatory diseases. What are the underlying business or industry changes driving this perspective?
내러티브 업데이트 • Jun 22
NKTR: Upcoming Autoimmune Data And Sector M&A Readthrough Will Drive Repricing
Analysts have adjusted their price targets on Nektar Therapeutics, with recent Street research citing sector readthroughs from the proposed $10.9b Apogee Therapeutics deal, along with updated assumptions for revenue growth, profit margin, and future P/E, to refine fair value expectations around $192.00 per share. Analyst Commentary Recent Street research around Nektar Therapeutics has been shaped by both company specific updates and broader sector moves, including the proposed US$10.9b Apogee Therapeutics transaction.내러티브 업데이트 • Jun 04
NKTR: Phase 3 Dermatology Programs And Liquidity Position Will Drive Future Upside
Analysts have raised their fair value estimate for Nektar Therapeutics from $144.25 to $153.25, reflecting updated assumptions on revenue trends, profitability, and valuation following a series of recent price target revisions and fresh coverage initiations. Analyst Commentary Recent research updates on Nektar Therapeutics show a mix of enthusiasm around the pipeline and caution around execution and valuation, which is reflected in both price target revisions and new coverage initiations.내러티브 업데이트 • May 18
NKTR: Future Phase 3 Autoimmune Data Will Drive Upside Repricing Potential
Narrative Update on Nektar Therapeutics The updated analyst price target for Nektar Therapeutics has shifted from a fair value of $165.00 to $192.00 as analysts factor in recent target changes across the Street and revisit assumptions around revenue growth, profit margins, discount rate and future P/E multiples. Analyst Commentary Recent Street research around Nektar Therapeutics clusters around the potential of its lead asset rezpegaldesleukin in atopic dermatitis and alopecia areata, as well as the implications for long term revenue and earnings power.분석 기사 • May 11
Earnings Update: Here's Why Analysts Just Lifted Their Nektar Therapeutics (NASDAQ:NKTR) Price Target To US$153
Shareholders might have noticed that Nektar Therapeutics ( NASDAQ:NKTR ) filed its quarterly result this time last...내러티브 업데이트 • May 01
NKTR: Phase 3 Atopic Dermatitis And Alopecia Data Will Drive Future Upside
Analysts have lifted Nektar Therapeutics' fair value estimate from $128.13 to $144.25 as multiple firms raised their price targets, pointing to rezpegaldesleukin data, an expanded Phase 3 plan in atopic dermatitis, and a clearer funding path as key drivers of their updated views. Analyst Commentary Recent Street research on Nektar Therapeutics has focused on rezpegaldesleukin, the planned Phase 3 program in atopic dermatitis, and updated funding assumptions, with several firms updating models and price targets.내러티브 업데이트 • Apr 16
NKTR: Future Phase 3 Atopic Dermatitis Data Will Drive Upside Repricing Potential
Analysts have lifted the base case fair value estimate for Nektar Therapeutics from $135 to $165, citing recent Street research that highlights rezpeg data in atopic dermatitis and alopecia, a Phase 3 plan in atopic dermatitis, and a series of higher price targets and upgrades across multiple firms. Analyst Commentary Recent Street research on Nektar Therapeutics has tilted clearly positive, with several firms lifting price targets and highlighting rezpegaldesleukin, or rezpeg, as the key driver for their valuation work.Seeking Alpha • Apr 15
Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive
Summary Nektar Therapeutics is poised for a key catalyst with upcoming REZPEG 52-week maintenance data in Alopecia Areata (AA) before April’s end. My base case model projects REZPEG will achieve a probability-adjusted 28% of patients reaching SALT <20, matching or exceeding low-dose baricitinib efficacy. REZPEG’s benign safety profile and lack of black box warning may offset slightly lower efficacy compared to JAK inhibitors in AA. A positive 52-week readout could drive NKTR shares 30–40% higher, as current valuation barely reflects AA potential. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 01
NKTR: Phase 3 Atopic Dermatitis Program And Data Strength Will Drive Future Upside
The analyst price target for Nektar Therapeutics has been adjusted from $136.43 to $128.13 as analysts factor in updated rezpegaldesleukin Phase 2 data, plans for a Phase 3 atopic dermatitis study, and recent Street research that refines expectations around future sales potential and valuation multiples. Analyst Commentary Recent Street research around Nektar Therapeutics clusters around rezpegaldesleukin, with analysts updating models on the back of Phase 2 atopic dermatitis data, longer term maintenance results and the planned Phase 3 program.내러티브 업데이트 • Mar 18
NKTR: Phase 3 Atopic Dermatitis Program Will Drive Future Upside Potential
The analyst fair value estimate for Nektar Therapeutics has shifted from $129.86 to $136.43, as analysts factor in higher modeled sales potential for rezpegaldesleukin in atopic dermatitis and alopecia, along with recent price target increases across several firms tied to progressing Phase 2 data and planned Phase 3 programs. Analyst Commentary Recent Street research around Nektar Therapeutics has focused on rezpegaldesleukin, with pricing models and risk assessments concentrating on its potential role in atopic dermatitis and alopecia as Phase 2 data matures and Phase 3 plans move forward.내러티브 업데이트 • Mar 04
NKTR: Rezpeg Durability In Atopic Dermatitis And Alopecia Will Drive Future Upside
Analysts have lifted their price targets on Nektar Therapeutics, with one moving from $105 to $150, citing stronger conviction in Rezpeg's durability data in Atopic Dermatitis and alopecia areata, a clearer financing profile, and a more supportive catalyst path that is reflected in a higher fair value estimate of about $130 per share. Analyst Commentary Bullish Takeaways Bullish analysts point to the 52 week maintenance data from the REZOLVE AD study as reinforcing confidence in Rezpeg's durability, which they see as a key input to their higher fair value estimates.내러티브 업데이트 • Feb 18
NKTR: Alopecia Areata Phase 2b Durability Will Drive Future Upside
Analysts have lifted their price target for Nektar Therapeutics by about $9, citing updated views on Rezpeg's durability, deepening clinical responses, and revised fair value assumptions as the key drivers of the change. Analyst Commentary Recent research updates show a cluster of upbeat views on Nektar Therapeutics, centered on Rezpeg's clinical profile and its potential role in Alopecia Areata and other indications.분석 기사 • Feb 12
Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up
Nektar Therapeutics ( NASDAQ:NKTR ) shares have had a really impressive month, gaining 81% after a shaky period...내러티브 업데이트 • Feb 04
NKTR: Future Alopecia Areata Data Will Drive Upside Repricing Potential
Analysts have raised their fair value estimate for Nektar Therapeutics to $135 from $120, citing revised revenue growth assumptions, a lower future P/E multiple of about 165, and additional upside potential from Rezpeg in Alopecia Areata, which has an estimated $300 million in possible peak sales. Analyst Commentary Recent Street research has leaned positive on Nektar Therapeutics, with bullish analysts pointing to Rezpeg in Alopecia Areata as a key upside driver supporting higher valuation assumptions.내러티브 업데이트 • Jan 20
NKTR: Alopecia Areata Phase 2b Data And Fast Track Will Drive Upside
Analysts have lifted their price target on Nektar Therapeutics from US$99 to US$121, citing Rezpeg's Phase 2b Alopecia Areata opportunity, its safety profile, durability potential, and an added 20% probability of success with about US$300m in estimated peak sales. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher US$121 price target as a reflection of added confidence in Rezpeg's Alopecia Areata opportunity and its potential to contribute meaningfully to Nektar's valuation over time.내러티브 업데이트 • Jan 06
NKTR: Phase 2b Alopecia Data And Fast Track Status Will Drive Upside
Analysts have increased their price target for Nektar Therapeutics to $121 from $99, citing updated assumptions around Rezpeg, including new Alopecia Areata Phase 2b expectations, a clean safety profile, durability potential, and added value for future sales. They also highlighted the ongoing impact of Rezpeg related clinical data on how investors frame the separate Lilly litigation.분석 기사 • Dec 25
More Unpleasant Surprises Could Be In Store For Nektar Therapeutics' (NASDAQ:NKTR) Shares After Tumbling 25%
Nektar Therapeutics ( NASDAQ:NKTR ) shareholders that were waiting for something to happen have been dealt a blow with...내러티브 업데이트 • Dec 17
NKTR: Upcoming Phase 2b Data Will Drive Upside Despite Litigation Uncertainty
Analysts have lifted their blended fair value estimate for Nektar Therapeutics from approximately $107 to $114 per share. They cite higher price targets driven by growing confidence in Rezpeg's Phase 2 data, its novel mechanism and safety profile, and incremental modeled peak sales, despite slightly more conservative long term revenue growth assumptions.내러티브 업데이트 • Dec 02
NKTR: Late-Stage Clinical Data Will Drive Upside Despite Litigation Delays
Analysts have raised their price target for Nektar Therapeutics from approximately $94 to $107 per share. They cite growing confidence in the commercial potential of Rezpeg following recent positive clinical data and reinforced differentiation from competitors.내러티브 업데이트 • Nov 18
NKTR: Positive Phase 2b Data Will Drive Momentum Amid Delayed Litigation
Analysts have raised their price target for Nektar Therapeutics from $69 to $99 per share. They cite recent positive clinical data and a stronger outlook for Rezpeg's competitive position in atopic dermatitis as the reasons for this adjustment.내러티브 업데이트 • Nov 03
NKTR: Upcoming Phase 2b Data Readouts Will Drive Renewed Upside Momentum
Analysts have raised their price target for Nektar Therapeutics to $99, up from $69. This change is attributed to positive Phase 2b study results for rezpegaldesleukin and increased confidence in its commercial potential.내러티브 업데이트 • Oct 20
Fast Track Immunology Asset Will Debut Amid Execution Risks
Nektar Therapeutics' analyst price target has been revised downward from $101.17 to $93.86 per share. Analysts cite recent clinical updates and ongoing litigation developments as key factors influencing their outlook.내러티브 업데이트 • Sep 19
Fast Track Immunology Asset Will Debut Amid Execution Risks
Nektar Therapeutics’ consensus price target has increased to $101.17, driven by positive Phase 2b REZOLVE-AD results for rezpegaldesleukin, which demonstrated robust efficacy and safety in atopic dermatitis, supporting increased conviction in its differentiated clinical and commercial profile. Analyst Commentary Bullish analysts are raising price targets following positive Phase 2b REZOLVE-AD data for rezpegaldesleukin, with all primary and secondary endpoints met and robust efficacy and safety demonstrated in moderate-to-severe atopic dermatitis.분석 기사 • Aug 28
Nektar Therapeutics' (NASDAQ:NKTR) 28% Share Price Surge Not Quite Adding Up
Nektar Therapeutics ( NASDAQ:NKTR ) shares have continued their recent momentum with a 28% gain in the last month...분석 기사 • Jun 11
Nektar Therapeutics (NASDAQ:NKTR) Shares Fly 29% But Investors Aren't Buying For Growth
Nektar Therapeutics ( NASDAQ:NKTR ) shareholders are no doubt pleased to see that the share price has bounced 29% in...분석 기사 • May 15
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be
Market forces rained on the parade of Nektar Therapeutics ( NASDAQ:NKTR ) shareholders today, when the analysts...분석 기사 • May 11
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's shaping up to be a tough period for Nektar Therapeutics ( NASDAQ:NKTR ), which a week ago released some...분석 기사 • Apr 04
Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding
To the annoyance of some shareholders, Nektar Therapeutics ( NASDAQ:NKTR ) shares are down a considerable 29% in the...
새로운 내러티브 • Apr 03
Phase IIb Data And FDA Fast-Track Will Spur Mixed Prospects
Fast-track designation and strategic partnerships could expedite REZPEG's market entry, enhancing near-term revenue and profit margins.분석 기사 • Feb 10
Lacklustre Performance Is Driving Nektar Therapeutics' (NASDAQ:NKTR) 34% Price Drop
To the annoyance of some shareholders, Nektar Therapeutics ( NASDAQ:NKTR ) shares are down a considerable 34% in the...주주 수익률
| NKTR | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | -6.0% | -3.4% | -0.9% |
| 1Y | 43.3% | 44.7% | 14.2% |
수익률 대 산업: NKTR은 지난 1년 동안 44.7%의 수익을 기록한 US Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: NKTR은 지난 1년 동안 14.2%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| NKTR volatility | |
|---|---|
| NKTR Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
안정적인 주가: NKTR는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: NKTR의 주간 변동성(7%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1990 | 63 | Howard Robin | www.nektar.com |
바이오 제약 회사인 넥타 테라퓨틱스는 미국과 국제적으로 면역 치료 분야의 의약품을 발굴하고 개발하는 데 주력하고 있습니다. 자가면역질환 및 염증성 질환 환자의 근본적인 면역체계 불균형을 치료하기 위해 임상 2b상 중인 레즈페갈데스루킨, 궤양성 대장염, 백반증, 다발성 경화증 치료를 위한 NKTR-0165, 자가면역질환 치료를 위한 NKTR-0166, 섬유성 질환 치료를 위한 NKTR-422, 고형암 및 거대 B세포 림프종 치료를 위한 NKTR-255를 개발 중입니다. 다케다제약, 아스트라제네카, UCB제약, F. 호프만-라로슈, 바우쉬 헬스 컴퍼니, 화이자, UCB제약(바이오젠), 브리스톨-마이어스 스퀴브, 머크 KGaA와 협력 계약을 체결하고 있습니다.
Nektar Therapeutics 기초 지표 요약
| NKTR 기초 통계 | |
|---|---|
| 시가총액 | US$2.38b |
| 순이익 (TTM) | -US$157.13m |
| 매출 (TTM) | US$54.59m |
43.6x
주가매출비율(P/S)-15.2x
주가수익비율(P/E)NKTR는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| NKTR 손익계산서 (TTM) | |
|---|---|
| 매출 | US$54.59m |
| 매출원가 | US$0 |
| 총이익 | US$54.59m |
| 기타 비용 | US$211.72m |
| 순이익 | -US$157.13m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -4.60 |
| 총이익률 | 100.00% |
| 순이익률 | -287.84% |
| 부채/자본 비율 | 6.4% |
NKTR의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/13 01:54 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Nektar Therapeutics는 32명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Richard Silver | Barclays |
| George Farmer | BMO Capital Markets Equity Research |
| Gregory Harrison | BofA Global Research |